On December 10, 2018 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported it will present data on its investigational anti-PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Congress, being held December 13-16 in Geneva, Switzerland (Press release, BeiGene, DEC 10, 2018, View Source;p=RssLanding&cat=news&id=2380046 [SID1234531983]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mini Oral Presentation:
Title: A Phase 1A/1B trial of Tislelizumab, an Anti-PD-1 Antibody (Ab), in Patients (Pts) With Advanced Solid Tumors
Presentation #: 70O
Session: Mini Oral Session (ID37)
Location: Room A, Geneva Palexpo
Date: Saturday, December 15
Time: 08:30 CET
Presenter: Chia-Chi Lin, M.D., Ph.D., National Taiwan University Hospital
Poster Presentation:
Title: Tislelizumab, an Anti-PD-1 Antibody, in Patients With Urothelial Carcinoma (UC): Results From an Ongoing Phase 1/2 Study
Presentation #: 76P
Session: Poster display session (ID 9)
Location: Foyer, Geneva Palexpo
Date: Friday, December 14
Time: 12:30 CET
Lead Author: Shahneen Sandhu, M.D., Peter MacCallum Cancer Centre-East Melbourne, East Melbourne, Victoria, Australia
About Tislelizumab
Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
Discovered by BeiGene scientists, tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. The new drug application (NDA) for tislelizumab in China for patients with R/R cHL has been accepted by the China National Medical Products Administration (NMPA, formerly known as CFDA) and granted priority review status. BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumors in the United States, Europe, Japan and the rest of world outside Asia